Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daclizumab Has Winning Efficacy In MS, But Safety Questions Linger

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen/Abbott multiple sclerosis candidate passed the relapse rate hurdle and showed surprisingly good disability progression data in the Phase II SELECT trial, but there are safety signals that could be a problem.
Advertisement

Related Content

Keeping Track: FDA Approval Activity Heats Up With Ocaliva, Zinbryta And More
U.S. Tysabri Labeling Updated With More PML Risk Info But No Reference To JCV Testing
Biogen Idec's BG-12 Results Up The Ante In The Oral MS Market
Biogen Idec's BG-12 Results Up The Ante In The Oral MS Market
Merck KGaA Pins Cladribine Hopes On Ongoing Studies After Complete Response Letter

Topics

Advertisement
UsernamePublicRestriction

Register

PS072745

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel